5HT3R antagonist for use in treating aneurysms and cardiovascular risk
Methods of treating or reducing risk of aneurysm, reducing cardiovascular risk, reducing serum cholesterol, reducing serum triglycerides, and/or reducing atherosclerotic plague in a subject involve administering to the subject an effective amount of a 5HT 3 R antagonist.
1. A method of treating or reducing risk of aneurysm, comprising: administering to a subject in need of such treatment or reduction of risk of aneurysm an effective amount of a 5HT 3 R antagonist or pharmaceutically-acceptable salt thereof.
2. The method of claim 1 , wherein the subject is identified as being at risk of aneurysm.
3. The method of claim 1 , wherein the subject is identified as having an aneurysm.
4. The method of claim 1 , wherein the subject is has a history of nicotine use.
5. The method of claim 1 , wherein the subject is identified as having hypercholesterolemia.
6. The method of claim 1 , wherein the subject is identified as having hypertriglyceridemia.
7. The method of claim 1 , wherein the subject is identified as having atherosclerotic plague.
8. The method of claim 1 , wherein 5HT 3 R antagonist is selected from the group consisting of: tropisetron, dolasetron, granisetron, ondansetron, palonosetron, and ramosetron.
9. A method of reducing cardiovascular risk, comprising: administering to a subject in need of such reduction of cardiovascular risk an effective amount of a 5HT 3 R antagonist or pharmaceutically-acceptable salt thereof.
10. The method of claim 9 , wherein the cardiovascular risk is nicotine-induced and/or the subject has a history of nicotine use.
11. The method of claim 9 , wherein the subject is identified as being at risk of aneurysm.
12. The method of claim 9 , wherein the subject is identified as having an aneurysm.
13. The method of claim 9 , wherein the subject is identified as having hypercholesterolemia.
14. The method of claim 9 , wherein the subject is identified as having hypertriglyceridemia.
15. The method of claim 9 , wherein the subject is identified as having atherosclerotic plague.
16. The method of claim 9 , wherein 5HT 3 R antagonist is selected from the group consisting of: tropisetron, dolasetron, granisetron, ondansetron, palonosetron, and ramosetron.
17. A method of reducing serum cholesterol, reducing serum triglycerides, and/or reducing atherosclerotic plague, comprising:
administering to a subject in need of such reduction of serum cholesterol, serum triglycerides, and/or atherosclerotic plague an effective amount of a 5HT 3 R antagonist or pharmaceutically-acceptable salt thereof.
18. The method of claim 17 , wherein the subject has been identified as having nicotine-induced cardiovascular risk and/or the subject has a history of nicotine use.
19. The method of claim 17 , wherein the subject is identified as having or being at risk of aneurysm.
20. The method of claim 17 , wherein 5HT 3 R antagonist is selected from the group consisting of: tropisetron, dolasetron, granisetron, ondansetron, palonosetron, and ramosetron.